

- B<sup>1</sup>
1. (amended) In a method which calls for administration of IFN- $\alpha$  to a subject, the improvement comprising co-administering an effective amount of an isolated immunostimulatory nucleic acid, wherein said isolated immunostimulatory nucleic acid is at least 8 nucleotides long and comprises a poly-G sequence at each end and a central palindromic sequence comprising an unmethylated CpG dinucleotide.

19. (amended) The improvement of claim 1, wherein the immunostimulatory nucleic acid has a sequence selected from the group consisting of

B<sup>2</sup>

ggGGGACGATCGTCgggggG	ODN 2216	SEQ ID NO:7
ggGGGACGATATCGTCgggggG	ODN 2245	SEQ ID NO:9
ggGGGACGAGCTCGTCgggggG	ODN 2247	SEQ ID NO:11
ggGGGACGATCGTTGgggggG	ODN 2252	SEQ ID NO:13
ggGGTCACCGGTGAgggggG	ODN 2300	SEQ ID NO:24
ggGGTCGACGTACGTCGAgggggG	ODN 2301	SEQ ID NO:25
ggGGACGTCGACGTgggggG	ODN 2306	SEQ ID NO:30
ggGTCGTCGACGAggggggG	ODN 2329	SEQ ID NO:33
ggGGTCGACGTCGACGTCGAGgggggG	ODN 2334	SEQ ID NO:36, and
ggGGACGACGTCGTGgggggG	ODN 2336	SEQ ID NO:37,

wherein each lower case letter represents phosphorothioate linkage and each upper case letter indicates phosphodiester linkage.

- B<sup>3</sup>
24. (amended) A method of supplementing IFN- $\alpha$  treatment of a subject, comprising administering to a subject in need of IFN- $\alpha$  treatment an effective amount of IFN- $\alpha$  and an isolated immunostimulatory nucleic acid, wherein said isolated immunostimulatory nucleic acid is at least 8 nucleotides long and comprises a poly-G sequence at each end and a central palindromic sequence comprising an unmethylated CpG dinucleotide.

- B<sup>4</sup>
65. (amended) A method of increasing efficacy of IFN- $\alpha$  treatment of a subject, comprising:  
administering to a subject in need of treatment with IFN- $\alpha$  a pharmaceutical composition comprising IFN- $\alpha$ , and

B4  
Cave

coadministering to the subject in need of such treatment a pharmaceutical composition comprising an immunostimulatory nucleic acid in an amount which, together with the administered IFN- $\alpha$ , is an effective IFN- $\alpha$  treatment, wherein the efficacy of the IFN- $\alpha$  treatment is greater than the efficacy of administering the same amount of IFN- $\alpha$  in the absence of coadministering the immunostimulatory nucleic acid, and wherein said immunostimulatory nucleic acid is at least 8 nucleotides long and comprises a poly-G sequence at each end and a central palindromic sequence comprising an unmethylated CpG dinucleotide.

---

82. (amended) A method of decreasing a dose of IFN- $\alpha$  effective for treating a subject, comprising:

B3

administering to a subject in need of treatment with IFN- $\alpha$  a pharmaceutical composition comprising IFN- $\alpha$ , and

coadministering to the subject in need of such treatment a pharmaceutical composition comprising an immunostimulatory nucleic acid in an amount which, together with the administered IFN- $\alpha$ , is an effective IFN- $\alpha$  treatment, wherein the amount of administered IFN- $\alpha$  is less than an amount of IFN- $\alpha$  required in the absence of coadministering the immunostimulatory nucleic acid, and wherein said immunostimulatory nucleic acid is at least 8 nucleotides long and comprises a poly-G sequence at each end and a central palindromic sequence comprising an unmethylated CpG dinucleotide.

---

103. (amended) A method of reducing an IFN- $\alpha$  treatment-related side effect in a subject receiving or in need of treatment with IFN- $\alpha$ , comprising

B6

administering to a subject in need of treatment with IFN- $\alpha$  a pharmaceutical composition comprising IFN- $\alpha$ , and

coadministering to the subject in need of such treatment a pharmaceutical composition comprising an immunostimulatory nucleic acid in an amount which, together with the administered IFN- $\alpha$ , is an effective IFN- $\alpha$  treatment, wherein an IFN- $\alpha$  treatment-related

Bleu  
side effect is reduced in comparison to the side effect when IFN- $\alpha$  is administered in the absence of coadministering the immunostimulatory nucleic acid, and wherein said immunostimulatory nucleic acid is at least 8 nucleotides long and comprises a poly-G sequence at each end and a central palindromic sequence comprising an unmethylated CpG dinucleotide.

---

B7  
176. (amended) A method of stimulating production of a plurality of type I interferon (IFN) subtypes, comprising contacting type I interferon producing cells (IPCs) with an amount of immunostimulatory nucleic acid effective to induce secretion of at least two type I interferons, wherein said immunostimulatory nucleic acid is at least 8 nucleotides long and comprises a poly-G sequence at each end and a central palindromic sequence comprising an unmethylated CpG dinucleotide.

---

B8  
199. (amended) A method of inhibiting IL-12 production, comprising contacting IL-12-producing cells, in the presence of interferon-producing cells under conditions in which the IL-12-producing cells normally produce IL-12, with an immunostimulatory nucleic acid in an amount effective for inducing secretion of type I interferon, wherein said immunostimulatory nucleic acid is at least 8 nucleotides long and comprises a poly-G sequence at each end and a central palindromic sequence comprising an unmethylated CpG dinucleotide.

---

B9  
202. (amended) A pharmaceutical composition, comprising an isolated nucleic acid having a sequence selected from the group consisting of:

ggGGGACGATCGTCgggggG	ODN 2216	SEQ ID NO:7
ggGGGACGATATCGTCgggggG	ODN 2245	SEQ ID NO:9
ggGGGACGAGCTCGTCgggggG	ODN 2247	SEQ ID NO:11
ggGGGACGATCGTTGggggG	ODN 2252	SEQ ID NO:13
ggGGTCACCGGTGAgggggG	ODN 2300	SEQ ID NO:24
ggGGTCGACGTACGTCGAgggggG	ODN 2301	SEQ ID NO:25
ggGGACGTCGACGTggggG	ODN 2306	SEQ ID NO:30
ggGTCGTCGACGAgggggG	ODN 2329	SEQ ID NO:33
ggGGTCGACGTCGACGTCGAGgggggG	ODN 2334	SEQ ID NO:36, and